[go: up one dir, main page]

AR108941A1 - 1H-PIRAZOLO [4,3-B] PYRIDINS AS PDE INHIBITORS1 - Google Patents

1H-PIRAZOLO [4,3-B] PYRIDINS AS PDE INHIBITORS1

Info

Publication number
AR108941A1
AR108941A1 ARP170101836A ARP170101836A AR108941A1 AR 108941 A1 AR108941 A1 AR 108941A1 AR P170101836 A ARP170101836 A AR P170101836A AR P170101836 A ARP170101836 A AR P170101836A AR 108941 A1 AR108941 A1 AR 108941A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluoroalkyl
optionally substituted
cyano
substituents selected
Prior art date
Application number
ARP170101836A
Other languages
Spanish (es)
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR108941A1 publication Critical patent/AR108941A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) donde L se selecciona entre el grupo que consiste en NH, CH₂, S y O; R¹ se selecciona entre el grupo que consiste en hidrógeno, alquilo C₁₋₅ lineal o ramificado, fluoroalquilo C₁₋₅ y cicloalquilo C₃₋₅ monocíclico saturado; R² se selecciona entre el grupo que consiste en alquilo C₁₋₈ lineal o ramificado, cicloalquilo C₃₋₈ monocíclico saturado, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo; todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en metilo, flúor, hidroxi, ciano y metoxi; R³ es metilo sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo, todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es metilo sustituido con un heteroarilo de 5 miembros que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es etilo sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o R³ es etilo sustituido con un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o L es CH₂ y R³ es NH que está sustituido con fenilo, piridonilo, piridinilo, pirimidinilo o pirazinilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano, alquilo C₁₋₃, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; o L es CH₂ y R³ es NH que está sustituido con un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₃ fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃ y alcoxi C₁₋₃; R⁴ es fenilo, piridinilo o piridonilo todos los cuales pueden estar opcionalmente sustituidos una o más veces con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, ciano alquilo C₁₋₄, fluoroalquilo C₁₋₄, deutereoalquilo C₁₋₄, fluoroalcoxi C₁₋₃, ciclopropiloxi, alcoxi C₁₋₃, deutereoalcoxi C₁₋₃ y -N-R⁵R⁶ en el que R⁵ y R⁶ se seleccionan cada uno independientemente entre H, alquilo C₁₋₃ y deutereoalquilo C₁₋₃; o R⁴ es un heteroarilo de 5 miembros, que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, ciano, alquilo C₁₋₄, fluoroalquilo C₁₋₄, deutereoalquilo C₁₋₄, fluoroalcoxi C₁₋₃, ciclopropiloxi, alcoxi C₁₋₃, deutereoalcoxi C₁₋₃ y -N-R⁵R⁶, en el que R⁵ y R⁶ se seleccionan cada uno independientemente entre H, alquilo C₁₋₃ y deutereoalquilo C₁₋₃; o R⁴ es un heterociclo saturado de 4, 5 ó 6 miembros, todos los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados entre oxo, alquilo C₁₋₄ y fluoroalquilo C₁₋₄; y sales farmacéuticamente aceptables de los mismos.Claim 1: A compound according to formula (1) wherein L is selected from the group consisting of NH, CH₂, S and O; R¹ is selected from the group consisting of hydrogen, linear or branched C₁₋₅ alkyl, C₁₋₅ fluoroalkyl and saturated monocyclic C₃₋₅ cycloalkyl; R² is selected from the group consisting of linear or branched C₁₋₈ alkyl, saturated monocyclic C₃₋₈ cycloalkyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl; all of which may be optionally substituted one or more times with one or more substituents selected from the group consisting of methyl, fluorine, hydroxy, cyano and methoxy; R³ is methyl substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl, all of which may be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C₁₋₃ alkyl, C₁₋ fluoroalkyl ₃, C₁₋₃ fluoroalkoxy and C₁₋₃ alkoxy; or R³ is methyl substituted with a 5-membered heteroaryl which is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, C₁₋₃ fluoroalkoxy and C₁₋₃ alkoxy; or R³ is ethyl substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl all of which may be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C₁₋₃ alkyl, C₁₋ fluoroalkyl ₃, C₁₋₃ fluoroalkoxy and C₁₋₃ alkoxy; or R³ is ethyl substituted with a 5-membered heteroaryl, which is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, C₁₋₃ fluoroalkoxy and C₁₋₃ alkoxy; or L is CH₂ and R³ is NH which is substituted with phenyl, pyridonyl, pyridinyl, pyrimidinyl or pyrazinyl all of which may be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano, C₁ alkyl ₋₃, C₁₋₃ fluoroalkyl, C₁₋₃ fluoroalkoxy and C₁₋₃ alkoxy; or L is CH₂ and R³ is NH which is substituted with a 5-membered heteroaryl, which is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, C₁₋₃ fluoroalkoxy and C₁₋ alkoxy ₃; R⁴ is phenyl, pyridinyl or pyridonyl all of which may be optionally substituted one or more times with one or more substituents selected from the group consisting of halogen, cyano C₁₋₄ alkyl, fluoroalkyl C₁₋₄, deutereoalkyl C₁₋₄, fluoroalkoxy C₁ ₋₃, cyclopropyloxy, C₁₋₃ alkoxy, C₁₋₃ deutereoalkoxy and -N-R⁵R in which R⁵ and R⁶ are each independently selected from H, C₁₋₃ alkyl and C₁₋₃ deutereoalkyl; or R⁴ is a 5-membered heteroaryl, which is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₄ alkyl, C₁₋₄ fluoroalkyl, C₁₋₄ deutereoalkyl, C₁₋₃ fluoroalkoxy, cyclopropyloxy, C₁₋₃ alkoxy , C₁₋₃ and -N-R⁵R⁶ deutereoalkoxy, wherein R⁵ and R⁶ are each independently selected from H, C₁₋₃ alkyl and C₁₋₃ deutereoalkyl; or R⁴ is a saturated 4, 5 or 6 membered heterocycle, all of which may be optionally substituted with one or more substituents selected from oxo, C₁₋₄ alkyl and C₁₋₄ fluoroalkyl; and pharmaceutically acceptable salts thereof.

ARP170101836A 2016-07-04 2017-07-03 1H-PIRAZOLO [4,3-B] PYRIDINS AS PDE INHIBITORS1 AR108941A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201600397 2016-07-04

Publications (1)

Publication Number Publication Date
AR108941A1 true AR108941A1 (en) 2018-10-10

Family

ID=63962977

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101836A AR108941A1 (en) 2016-07-04 2017-07-03 1H-PIRAZOLO [4,3-B] PYRIDINS AS PDE INHIBITORS1

Country Status (2)

Country Link
AR (1) AR108941A1 (en)
MA (1) MA45537B1 (en)

Also Published As

Publication number Publication date
MA45537B1 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
AR095311A1 (en) 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS MUTANT HDI INHIBITORS
AR108109A1 (en) 1,5-DIHIDRO-4H-PIRAZOLO [3,4-D] PIRIMIDIN-4-ONAS AND 1,5-DIHIDRO-4H-PIRAZOLO [4,3-C] PIRIDIN-4-ONAS AS PDE1 INHIBITORS
AR108388A2 (en) OXAZOL COMPOUNDS REPLACED WITH INDAZOL AS INHIBITORS OF PI3-KINASES
AR094911A1 (en) SALTS OF DERIVATIVES OF 2-AMINO-1-HYDROXYETYL-8-HYDROXYQUINOLIN-2 (1H) -ONE THAT HAVE AGRICULTURAL ACTIVITY OF THE ADRENERGICAL RECEIVER B2 AS WELL AS ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEIVER M₃
AR112348A1 (en) BICYCLIC COMPOUNDS OF PIRAZOLO AND TRIAZOLO AS INHIBITORS OF JAK KINASES
AR096684A1 (en) COMPOUNDS TO TREAT SPINAL MUSCLE ATROPHY
AR089671A1 (en) 1,4-DIHIDROPIRIMIDINAS 4,4-DISUSTITUIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AR094342A1 (en) USEFUL BORONIC ACID DERIVATIVES AS ANTIMICROBIAL AGENTS
AR090220A1 (en) SERINA / TREONINA CINASA INHIBITORS
AR091271A1 (en) PIRROLOPIRIMIDONA AND PIRROLOPIRIDONA, TANQUIRASA INHIBITORS
AR088828A1 (en) CYCLHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS
AR092270A1 (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AR091519A1 (en) TANQUIRASA PIRROLOPIRAZONA INHIBITORS
AR094812A1 (en) DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
AR096152A1 (en) PURINA DERIVATIVES
AR105991A1 (en) HETEROARILOS REPLACED WITH PIRAZOLILO AND ITS USE AS MEDICATIONS
AR101392A1 (en) COMPOUNDS OF 6,7-DIHYDROPIRAZOLO [1,5-A] PIRAZIN-4 (5H) -ONA AND ITS USE AS NEGATIVE ALOSTERIC MODULATORS OF mGluR2 RECEPTORS
AR113931A1 (en) COMBINATION TREATMENTS INCLUDING THE ADMINISTRATION OF 1H-PIRAZOLO [4,3-B] PYRIDINES
AR103742A1 (en) DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA
AR087274A1 (en) DERIVATIVES OF AMETAS HETEROCICLICAS AS ANTAGONISTAS OF RECEPTORS P2X7
AR096153A1 (en) PIRROLO DERIVATIVES [2,3-D] PYRIMIDINE
AR101359A1 (en) DERIVATIVES OF 2-OXA-5-AZABICICLO [2.2.1] HEPTAN-3-ILO
AR093035A1 (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
AR094797A1 (en) PIRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS
AR095267A1 (en) INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODESTERASE

Legal Events

Date Code Title Description
FB Suspension of granting procedure